灵康药业
(603669)
| 流通市值：31.91亿 | | | 总市值：31.91亿 |
| 流通股本：7.12亿 | | | 总股本：7.12亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 86,535,882.34 | 322,483,887.6 | 281,860,683.71 | 171,607,603.84 |
| 营业收入 | 86,535,882.34 | 322,483,887.6 | 281,860,683.71 | 171,607,603.84 |
| 二、营业总成本 | 83,969,840.24 | 490,562,003.63 | 328,175,187.22 | 209,257,335.21 |
| 营业成本 | 61,573,676.62 | 181,515,762.37 | 158,059,489.06 | 140,924,941.42 |
| 税金及附加 | 949,021.72 | 4,189,910.55 | 2,126,217.21 | 1,506,711.45 |
| 销售费用 | 4,157,824.12 | 154,808,685.74 | 94,192,649.8 | 15,787,866.5 |
| 管理费用 | 9,780,399.91 | 74,612,084.15 | 52,547,123.1 | 35,884,284.09 |
| 研发费用 | 2,055,959.46 | 12,701,213.38 | 5,982,143.02 | 5,029,204.5 |
| 财务费用 | 5,452,958.41 | 62,734,347.44 | 15,267,565.03 | 10,124,327.25 |
| 其中:利息费用 | 5,461,824.89 | 21,197,524.07 | 15,436,726.46 | 10,272,529.67 |
| 其中:利息收入 | 20,425.75 | 237,874.25 | 205,129.83 | 164,975.18 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,495,886.93 | -570,782.06 | 4,755,688.98 | -347,222.93 |
| 加:投资收益 | -132,297.56 | -2,407,842.88 | -3,303,961.09 | -3,046,508.71 |
| 资产处置收益 | 82,662.06 | 3,533,141.93 | 2,520,416.75 | -49,322.73 |
| 资产减值损失(新) | 327,110.24 | -41,449,843.73 | -4,491.55 | -107,822.6 |
| 信用减值损失(新) | -1,550,910.24 | 914,989.13 | -5,825,867.31 | -3,997,851.07 |
| 其他收益 | 762,747.04 | 12,084,600.62 | 10,870,010.66 | 10,331,669.39 |
| 四、营业利润 | 3,551,240.57 | -195,973,853.02 | -37,302,707.07 | -34,866,790.02 |
| 加:营业外收入 | 0.09 | 4,204,002.34 | 4,202,744.34 | 2,698.12 |
| 减:营业外支出 | 397,335.13 | 1,744,582 | 1,402,797.26 | 1,102,127.53 |
| 五、利润总额 | 3,153,905.53 | -193,514,432.68 | -34,502,759.99 | -35,966,219.43 |
| 减:所得税费用 | 198,000.01 | -275,081.29 | 385.53 | -232,533.66 |
| 六、净利润 | 2,955,905.52 | -193,239,351.39 | -34,503,145.52 | -35,733,685.77 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 2,955,905.52 | -193,239,351.39 | -34,503,145.52 | -35,733,685.77 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 2,955,905.52 | -193,239,351.39 | -34,503,145.52 | -35,733,685.77 |
| 扣除非经常损益后的净利润 | 1,013,706.46 | -170,095,301.28 | -56,453,978.08 | -45,544,900.33 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0 | -0.27 | -0.05 | -0.05 |
| (二)稀释每股收益 | 0 | -0.27 | -0.05 | -0.05 |
| 八、其他综合收益 | - | 2,004,742.18 | - | - |
| 归属于母公司股东的其他综合收益 | - | 2,004,742.18 | - | - |
| 九、综合收益总额 | 2,955,905.52 | -191,234,609.21 | -34,503,145.52 | -35,733,685.77 |
| 归属于母公司股东的综合收益总额 | 2,955,905.52 | -191,234,609.21 | -34,503,145.52 | -35,733,685.77 |
| 公告日期 | 2026-04-29 | 2026-04-29 | 2025-10-31 | 2025-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |